Last updated: February 20, 2026
What is the current development stage of ABBV-951?
ABBV-951, developed by AbbVie, is an experimental drug candidate aimed at treating Parkinson’s disease. As of the latest data, it remains in early clinical development phases, specifically Phase 1/2 trials initiated in 2021. The trials assess its safety, tolerability, pharmacokinetics, and preliminary efficacy.
When are key clinical milestones expected?
- Phase 1 completion: Expected mid-2023, with initial safety data.
- Phase 2 initiation: Anticipated late 2023, contingent on Phase 1 results.
- Phase 2 completion: Likely around 2025, with primary endpoint data.
What is the mechanism of action?
ABBV-951 is a selective, sustained-release formulation of a dopamine receptor modulator designed to provide continuous symptom control in Parkinson’s patients. It aims to reduce motor fluctuations associated with standard therapies like levodopa.
How does ABBV-951 compare to existing treatments?
| Aspect |
ABBV-951 |
Standard Parkinson’s Treatment |
| Mechanism |
Dopamine receptor modulation, sustained release |
Levodopa, dopamine agonists |
| Delivery method |
Oral, extended-release formulation |
Oral tablets, injections |
| Targeted outcomes |
Motor fluctuations, symptom control |
Symptom relief, with fluctuating effects |
What are the regulatory prospects?
AbbVie plans to submit an Investigational New Drug (IND) application to the FDA by late 2022. Given the unmet need for sustained-release formulations with fewer motor fluctuations, regulatory agencies may prioritize review if early safety data are positive.
How large is the market for Parkinson’s treatments?
The global Parkinson’s disease drug market was valued at approximately USD 4.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2022 to 2027, reaching USD 6.5 billion. The primary drivers include rising disease prevalence, aging populations, and demand for formulations that reduce motor fluctuations.
| Market Drivers |
Effect |
| Aging global population |
Increased Parkinson’s prevalence |
| Currently available treatments’ limitations |
Need for improved drug delivery systems |
What is the competitive landscape?
Key competitors include:
- AbbVie’s own treatments, such as Duopa (carbidopa/levodopa) infusion.
- Eli Lilly’s ongoing development of dopamine receptor drugs.
- UCB Pharma’s clonidine patches for Parkinson’s symptoms.
ABBV-951’s potential advantages are its oral administration and sustained-release profile, aiming for better patient adherence and fewer motor fluctuations.
What is the market entry potential?
If ABBV-951 demonstrates safety and efficacy, it could secure a niche in early to mid-stage Parkinson’s disease management. The drug will face competition from established therapies and emerging precision medicine approaches.
Regulatory approval hinges on phase 2 results, expected in 2025, with commercialization potentially beginning in 2026.
Market projection and revenue estimates
Assuming successful clinical trials and regulatory approval, revenues could reach USD 500 million annually by 2030, capturing 7–10% of the Parkinson’s drug market. This projection incorporates:
- Estimated market size of USD 6.5 billion in 2027.
- Launch in key markets: US, Europe, Japan.
- Adoption rate based on patient preference for oral, sustained-release therapies.
Key risks and considerations
- Delays or failures in clinical trials.
- Competition from new therapies with improved profiles.
- Regulatory delays or unfavorable safety data.
- Market acceptance influenced by existing treatment efficacy and cost.
Key Takeaways
- ABBV-951 is in early clinical trials targeting motor fluctuations in Parkinson’s disease.
- It offers a sustained-release, oral formulation aiming to improve patient adherence.
- Market potential is significant, contingent on successful trial outcomes and regulatory approval.
- Market estimates suggest revenues could reach USD 500 million annually post-approval.
- Competitive landscape centered on traditional therapies and innovative delivery systems.
FAQs
Q1. When is ABBV-951 expected to reach the market?
Potential commercialization could occur around 2026, following positive phase 2 trial outcomes and regulatory approval.
Q2. How does ABBV-951 differ from existing Parkinson’s treatments?
It provides a sustained-release oral formulation designed to reduce motor fluctuations, improving continuous symptom control.
Q3. What are the main risks for ABBV-951’s development?
Risks include clinical trial failures, safety concerns, regulatory delays, and market competition.
Q4. Which regions will ABBV-951 target first?
Initial focus will be on the US, Europe, and Japan, key markets for Parkinson’s drugs.
Q5. How does the market size influence ABBV-951’s investment potential?
A growing Parkinson’s drug market with unmet needs increases prospects for revenue and market penetration.
References
- Market Research Future. (2022). Parkinson’s Disease Market Analysis.
- FDA. (2021). Investigational New Drug Application Process.
- GlobalData. (2022). Parkinson’s Disease Drug Forecast.
- AbbVie Inc. (2022). Clinical Trial Registry and Investor Presentation.
